Procarta’s innovative approach to antimicrobial discovery opens up bacterial transcription as a new therapeutic target. We are developing novel drugs that are active against resistant strains, have a controllable microbiological spectrum and are designed by a rapid and rational process.
Oligonucleotide Transcription Factor Decoys (TFDs) contain binding sites for essential bacterial transcription factors. When delivered into bacterial cells they inhibit these molecules to prevent expression of genes needed for the bacteria to survive and cause infection. Delivery is achieved with Procarta’s proprietary nanoparticles.
These novel antimicrobials are specifically designed to help address the worldwide healthcare crisis of rising antimicrobial resistance (AMR).